New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 7, 1998, Pages 745-750

  Edwards, James P ^a   West, Sarah J ^a   Pooley, Charlotte L F ^a   Marschke, Keith B ^a   Farmer, Luc J ^a,b   Jones, Todd K ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (TRIFLUOROMETHYL) 2(1H) PYRROLIDINO[3,2 G]QUINOLINONE DERIVATIVE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; HORMONE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL STRAIN COS1; CHEMICAL MODIFICATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; CELL LINE; DRUG DESIGN; FLUTAMIDE; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR STRUCTURE; PYRROLIDINES; QUINOLINES; QUINOLONES; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 0032492668     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00107-3     Document Type: Article

References (19)

1. 2. Hamann, L. G.; Higuchi, R. I.; Zhi, L.; Edwards, J. P.; Wang, X.-N.; Marschke, K. B.; Kong, J. W.; Farmer, L. J.; Jones, T. K. J. Med. Chem., 1998. 41, in press.
2. 3. (a) Neri, R.; Peets, E.; Watnick. A. Biochem. Soc. Trans. 1979, 7, 565.
3. (b) Neri, R.; Peets, E. A. J. Steroid Biochem. 1975, 6. 815.
4. 4. (a) Kaisary, A. V. Prostate Suppl. 1994, 5. 27.
5. (b) Lungimayr, G. Anti-Cancer Drugs 1995, 6. 508.
6. 5. (a) Tenover, J. S. J. Clin. Endocrinol. Metab. 1992, 75, 1092.
7. (b) Bhasin, S. J. Clin. Endocrinol. Metab. 1992, 74, 1221.
8. (c) Bhasin, S.: Bremner, W. J. J. Clin. Endocrinol. Metab. 1997. 82, 3.
9. 6. Rogers, C. U.; Corson, B. B. Org. Synth., Coll. Vol. IV 1963, 884.
10. 7. Gribble, G. W.; Lord. P. D.; Skotnicki, J.; Dietz, S. E.; Eaton, J. T.; Johnson, J. L. J. Am. Chem. Soc.. 1974, 96, 7812.
11. 8. The relative stereochemistry of all diastereomeric compounds in this paper was unambiguously assigned by NOE experiments.
12. 9. Hauser, C. R.; Reynolds, G. A. J. Am. Chem. Soc. 1948, 70. 2402.
13. 6 10.85 (br s, 1H), 7.34 (s, 1H), 6.61 (s, 1H), 6.49 (s, 1H). 5.92 (s, 1H), 3.87 (m, 1H), 3.17 (dd. J = 13.6, 6.8. 1H), 1.85-1.70 (m, 3H), 1.56 (m, 2H), 1.44 (m, 3H).
14. 11. Larock, R. C.; Srinivasan. B. Tetrahedron Lett. 1987, 28, 5291.
15. 12. Berger, T. S.; Parandoosh, Z.; Perry, B. W.; Stein, R. B. J. Steroid Biochem. Mol. Biol. 1992, 41, 733.
16. 13. For lead references to the family of closely related intracellular receptors to which the androgen receptor belongs, see: (a) McDonnell, D. P.: Vegeto, E.; Gleeson, M. A. G. Bio/Technology 1993, 11, 1256.
17. (b) Rosen, J.; Day, A.: Jones, T. K.; Jones, E. T. T.; Nadzan, A. M.; Stein, R. B. J. Med Chem. 1995, 38, 4855.
18. 14. A complete description of these assays, including materials and methods, can be found in reference 2.
19. 15. The in vitro agonist activity of 16 has been confirmed in vivo using a rodent model (castrated rat acute LH suppression assay): Wang, X.-N., unpublished results.